The ends of mRNAs may prevent the beginnings of cancer

August 20, 2009

The tail ends of cellular protein templates, regions often thought relatively inconsequential, may actually play a role in preventing normal cells from becoming cancerous.

The finding from scientists at Whitehead Institute for Biomedical research is reported in the August 20 edition of Cell.

Proteins are made from templates that are copied from a cell's DNA. These templates, called messenger RNAs (mRNAs), comprise three sections. The middle section codes for the actual protein, while the beginning and end sections are known as untranslated regions (UTRs) because they do not code for any portion of the protein. Instead, the beginning section gets started, while the tail section, called the 3'UTR, appeared simply to be along for the ride.

"This end of the mRNA is often not considered that important because if you put the beginning and middle of the mRNA into a cell, you get the right protein," says Christine Mayr, first author of the Cell paper and a former postdoctoral researcher in the lab of Whitehead Member David Bartel. "But now we know that this end often has a protein production regulatory program and in some cases can play a role in cancer."

A cell uses proteins in almost all of its processes, from cell division, to transporting essential molecules, to providing the cell's structure. Because the cell's protein production profile is tightly controlled and specific to the cell's type and stage in its life cycle, the over- or under-production of certain proteins can alter normal cellular function. These changes can include uncontrolled cell division and the ability to grow in the absence of a substrate—both defining traits of cancer cells.

When Mayr compared mRNAs produced in normal cells with those in , she noticed that the tail end of the cancer cells' mRNAs were cut short. In some cases, nearly 95% of the 3'UTR was missing.

"So now, in the cancer cell, the same protein is being made, but a lot of regulatory sequences have been lost," says Mayr. "And in the beginning, I had no idea what this means. But then I found that those shorter mRNAs were making much more protein."

In fact, the shorter mRNAs were producing between two and 40 times more protein than their normal-length counterparts. When Mayr altered normal cells so they produced only shortened mRNAs for a specific gene, the cells again produced huge amounts of that mRNA's protein. And the copious proteins transformed normal cells into cancer-like cells.

"So, my theory is that in normal cells, genes are tightly regulated by their long 3'UTRs," says Mayr. "And the cancer cell somehow has the ability to express the shorter without those regulatory sequences. Without that regulation, it's able to express large quantities of ."

Although Mayr has established a connection between short 3'UTRs and cancer cells, how the cells shorten their mRNAs remains a mystery.

"The next step is to try to explain this phenomenon mechanistically," says Bartel, who is also a professor of biology at MIT and a Howard Hughes Medical Institute investigator. "There has to be biochemical machinery that causes shortened 3'UTRs in cancer cells, something that the cancer cells have that normal cells don't have. Right now, the biochemical cause of this is not known."

More information: "Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer ," Cell, published August 21, 2009; Christine Mayr and David P. Bartel.

Source: Whitehead Institute for Biomedical Research (news : web)

Related Stories

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
not rated yet Aug 21, 2009
The shortend "tails" could be less electrons!
Excess "free electrons" are suspect in the
accellerated mitosis of cancer!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.